Analyst Emily Bodnar from H.C. Wainwright maintained a Buy rating on Femasys (FEMY – Research Report) and decreased the price target to $12.00 from $15.00.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Emily Bodnar has given her Buy rating due to a combination of factors that highlight Femasys’s potential for growth. Despite lower than expected overall sales in the first quarter of 2025, the company reported a significant 78% quarter-over-quarter increase in U.S. revenues, indicating positive market momentum. This growth is supported by strategic partnerships with fertility conglomerates, which are anticipated to contribute to sales later in the year as these collaborations mature.
Additionally, Femasys’s recent achievements in the European market bolster the Buy rating. The company has secured EU approval for its FemBloc delivery system and established distribution partnerships in Spain, paving the way for future commercialization. These partnerships are expected to facilitate a smooth market entry due to the distributors’ previous experience with similar products. The expansion of Femasys’s commercial team in Europe further supports the potential for additional partnerships in key EU markets, enhancing the company’s growth prospects.